{"id":"W4379281566","doi":"10.1200/jco.2023.41.16_suppl.tps5633","title":"The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN14<sup>2</sup>): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Medicine; Clinical endpoint; Endometrial cancer; Radiation therapy; Internal medicine; Interim analysis; Oncology; Durvalumab; Hazard ratio; Cancer; Surgery; Urology; Randomized controlled trial; Immunotherapy; Pembrolizumab; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001729268,0.001182213,0.001424383,0.0002942313,0.0002280163,0.0006691955,0.0008117913,0.001170575,0.006563136],"category_scores_gemma":[0.001077069,0.0002934822,0.001286632,0.0002812071,0.0007297436,0.0005337814,0.0004508007,0.001827259,0.000956283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00108524,"about_ca_system_score_gemma":0.001348425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001404182,"about_ca_topic_score_gemma":0.004516668,"domain_scores_codex":[0.9995399,0.0002906978,0.000009671987,0.00005575715,0.00003297905,0.00007111047],"domain_scores_gemma":[0.999525,0.0001080896,0.0001381613,0.00004429235,0.0000187803,0.0001656642],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9033253,0.008178927,0.003144021,0.001606836,0.001425132,0.0001100348,0.00008689819,0.001180495,0.006820065,0.0005667512,0.01129484,0.06226058],"study_design_scores_gemma":[0.9339703,0.05441648,0.004387981,0.0001046921,0.0004470641,0.0001091588,0.00002104195,0.0004288996,0.000664524,0.0002659618,0.005171213,0.00001277969],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9484927,0.02342152,0.001054375,0.003597168,0.0007660691,0.006184627,0.006826506,0.0002702658,0.009386756],"genre_scores_gemma":[0.9572572,0.007123872,0.004468694,0.005367756,0.0006075673,0.007608823,0.007906696,0.00008701091,0.009572401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006563136,"threshold_uncertainty_score":0.02195585,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08732168933804182,"score_gpt":0.439131631849102,"score_spread":0.3518099425110602,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}